40 filings · most recent first
IONS 8-K Filings
Ionis Pharmaceuticals Reports Q2 2026 Financial Results And Key Program Updates
Ionis Pharmaceuticals Reaffirms 2026 Financial Guidance
Ionis Pharmaceuticals Eplontersen Phase 3 Trial Fails To Meet Primary Endpoint
Ionis Pharmaceuticals Receives Fda Approval For Tryngolza To Treat Severe
Ionis Pharmaceuticals Presents Positive Longterm Data For Olezarsen In Severe
Ionis Pharmaceuticals Appoints Ludwig Hantson To Board Of Directors
Ionis Pharmaceuticals Announces Positive Pivotal Data For Bepirovirsen In
Ionis Pharmaceuticals Reports Strong Q1 2026 Financial Results And Key Program
Ionis Pharmaceuticals Announces Positive Results For Zilganersen In Alexander
Ionis Pharmaceuticals Announces Board Member Retirements And New Appointment
Ionis Pharmaceuticals Reports Q4 And Full Year 2025 Financial Results And
Ionis Pharmaceuticals Announces Preliminary 2025 Us Net Sales Of 105M For
Ionis Pharmaceuticals Announces Positive Phase 3 Results For Hepatitis B
Ionis Pharmaceuticals Announces 770M Private Offering Of Convertible Senior
Ionis Pharmaceuticals Announces Completion Of Public Offering
Ionis Pharmaceuticals Announces Public Offering Of Common Stock
Ionis Pharmaceuticals Announces Positive Phase 3 Results For Olezarsen In
Ionis Pharmaceuticals Inc Announces Advisory Services Agreement With Richard
Ionis Pharmaceuticals Reports Q3 2025 Financial Results With Increased Revenue
Ionis Pharmaceuticals Announces Positive Topline Results For Zilganersen In
Ionis Pharmaceuticals Announces Positive Results For Olezarsen In Phase 3
Fda Approves Dawnzera For Hae Prophylaxis
Ionis Pharmaceuticals Reports Strong Q2 2025 Results And Raises Fullyear
Ionis Pharmaceuticals Announces Executive Leadership Transition
Ionis Pharmaceuticals Annual Meeting Voting Results Announced
Ionis Pharmaceuticals Announces Positive Topline Results From Olezarsen Study
Ionis Pharmaceuticals Reports Q1 2025 Financial Results
Ionis Pharmaceuticals Enters License Agreement With Ono For Sapablursen
Ionis Pharmaceuticals Reports Q4 And Full Year 2024 Financial Results And
Ionis Pharmaceuticals Announces Fda Approval Of Tryngolza For Familial
Ionis Pharmaceuticals Reports Third Quarter 2024 Financial Results And Provides
Ionis Pharmaceuticals Reports Q2 2024 Financial Results And Business Updates
Ionis Pharmaceuticals Expands Licensing For Investigational Hae Medicine With
Ionis Pharmaceuticals Annual Meeting Results Announced
Ionis Pharmaceuticals Announces Positive Results From Oasishae And Oasisplus
Ionis Pharmaceuticals Announces Q1 2024 Financial Results And Pipeline Updates
Ionis Pharmaceuticals Announces Positive Phase 3 Results For Olezarsen In Fcs
Ionis Pharmaceuticals Announces Key Executive Appointments And Advisory
Ionis Pharmaceuticals Reports 2023 Financial Results And Provides 2024 Guidance
Ionis Pharmaceuticals Announces Positive Topline Results For Hae Treatment